8-K: NovaBay Pharmaceuticals Implements 1-for-35 Reverse Stock Split

NovaBay Pharmaceuticals has completed a 1-for-35 reverse stock split, effective May 30, 2024, to maintain its NYSE American listing.

Summary

• NovaBay Pharmaceuticals executed a 1-for-35 reverse stock split.
• The reverse stock split became effective at 4:15 p.m. Eastern Time on May 30, 2024.
• The company's board of directors approved the reverse stock split on May 28, 2024, following stockholder approval at the annual meeting on the same day.
• Every 35 shares of outstanding common stock were combined into one share.
• No fractional shares were issued; instead, shareholders received an additional whole share.
• The total number of authorized shares remains unchanged at 150,000,000.
• Trading on a split-adjusted basis began on May 31, 2024, on the NYSE American exchange.
• The trading symbol 'NBY' remains the same, but the CUSIP number is now 66987P 409.

Sentiment

Score: 5

Explanation: The document describes a reverse stock split, which is a neutral event. It is a necessary action to maintain listing compliance but does not inherently indicate positive or negative sentiment.

Positives

• The reverse stock split was approved by both the board of directors and stockholders.
• The company ensured no fractional shares were issued by rounding up to the nearest whole share.
• The company's trading symbol remains the same, minimizing confusion for investors.

Risks

• Reverse stock splits can sometimes be perceived negatively by the market, potentially impacting investor confidence.
• The company's share price may experience volatility following the reverse stock split.

Management Comments

• The company's CEO and General Counsel, Justin M. Hall, signed the report on behalf of NovaBay Pharmaceuticals.

Industry Context

Reverse stock splits are a common corporate action for companies seeking to maintain listing compliance on major exchanges, often when share prices fall below minimum thresholds. This action is not uncommon in the pharmaceutical industry, particularly for smaller companies.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism used by companies listed on exchanges like NYSE American to maintain compliance with minimum share price requirements.
• Other companies in the pharmaceutical sector, such as Aeterna Zentaris and Ocular Therapeutix, have also undertaken reverse stock splits to address low share prices.
• The 1-for-35 ratio is within the range of reverse stock splits seen in the industry, which can vary from 1-for-2 to 1-for-100.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership remains the same, except for adjustments due to fractional shares.
• The reverse stock split is intended to help the company maintain its listing on the NYSE American, which is important for investor confidence.

Key Dates

Keywords

reverse stock split, common stock, NBY, NYSE American, stockholders, certificate of amendment, corporate action